[Platelet aggregation inhibitors in diabetes mellitus]

Area of Science:

• Cardiology
• Diabetology
• Pharmacology

Background:

• Diabetic patients face higher risks of cardiovascular complications and ischemic events.
• Platelets in diabetic individuals are in a persistent prethrombotic state, driving arterial thrombus formation.
• Acute coronary syndromes are pathologically linked to platelet activation, aggregation, and thrombus development.

Purpose of the Study:

• To review the efficacy of antithrombotic agents in diabetic patients.
• To highlight the benefits of newer antithrombotic drugs and combination therapies.
• To emphasize the need for early and preventive antithrombotic strategies in diabetes.

Main Methods:

• Review of landmark trials (e.g., Antiplatelet Trialist's Collaboration, CAPRIE) evaluating antithrombotic agents.
• Analysis of studies on newer drugs like clopidogrel and glycoprotein IIb/IIIa receptor inhibitors.
• Examination of evidence for combination therapies in acute settings like myocardial infarction reperfusion.

Main Results:

• Aspirin (75-325 mg daily) reduces vascular events by 25%-34%.
• Clopidogrel showed a slight advantage over aspirin in the CAPRIE trial.
• Glycoprotein IIb/IIIa inhibitors offer significant benefits, particularly in diabetic patients, and enhance reperfusion when combined with thrombolytics.

Conclusions:

• Diabetic patients require earlier antithrombotic therapy compared to non-diabetics.
• Effective antithrombotic medications are readily available for this high-risk group.
• Primary prevention with antithrombotic therapy should be strongly considered for diabetic patients.